Official Title
An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
Brief Summary

This study will provide pre-approval drug access to lapatinib, in combination withcapecitabine, to patients whose breast cancer had progressed on other therapies

Approved for marketing
Neoplasms, Breast

Drug: lapatinib + capecitabine

Experimental

Eligibility Criteria

Inclusion criteria:

- May have received prior lapatinib in another trial. Previous capecitabine (as
previous agent or non-lapatinib containing regimen) is also permitted.

- Prior treatment with hormonal therapy is allowed.

- Must have advanced or metastatic breast cancer with progression (as assessed by
modified RECIST) after prior therapy, which must include all of the following: prior
treatment with an anthracycline, a taxane, and trastuzumab alone or in combination
with other therapy. Trastuzumab must have been administered in the adjuvant, or
locally advanced or metastatic setting.

- Must have tumors that overexpress ErbB2 defined as +3 by IHC or FISH positive for
ErbB2 gene amplification. The status of ErbB2 expression must be documented prior to
study entry.

- Must be >/= 18 years of age

- Life expectancy of > 8 weeks

- Must have recovered from side effects of previous treatment

- Patients with CNS mets are eligible provided treatment with prohibited medications
as listed in the protocol are not required

- Cardiac ejection fraction must be within the institutional range of normal as
measured by ECHO. MUGA scans are allowed if ECHOs cannot be performed

- Able to swallow and retain oral medications

- Must have adequate hematologic, hepatic and renal function

Exclusion criteria:

- Pregnant or lactating females

- Malabsorption syndrome, disease significantly affecting GI function, or resection of
the stomach or bowel, or ulcerative colitis

- Concurrent disease or condition that would make the patient inappropriate for study
participation

- Unresolved or unstable toxicity from prior administration of another investigational
drug and/or prior cancer treatment

- Uncontrolled infection

- Active cardiac disease defined as history of uncontrolled or symptomatic angina;
history of arrhythmias requiring medication, or clinically significant, with the
exception of asymptomatic atrial fibrillation requiring anticoagulation; MI < 6
months from study entry; uncontrolled or symptomatic CHF; ejection fraction below
the institutional normal limit; any other cardiac condition that would make this
protocol unreasonably hazardous for the patient

- Receiving concurrent chemotherapy (other than capecitabine), radiation therapy,
immunotherapy, biologic therapy or hormonal therapy for cancer. Concurrent therapy
with bisphosphonates is allowed

- History of allergic reaction attributed to compounds of similar composition to
lapatinib or any excipients

- History of allergic reactions attributed to compounds of similar chemical
composition to capecitabine, fluorouracil or excipients

- Known DPD deficiency

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
Chile
China
Cyprus
Czech Republic
Denmark
Estonia
Finland
Germany
Greece
Hong Kong
Iceland
Indonesia
Ireland
Israel
Italy
Korea, Republic of
Luxembourg
Malaysia
Malta
Mexico
Netherlands
New Zealand
Peru
Philippines
Poland
Portugal
Romania
Russian Federation
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan
Thailand
Ukraine
United Kingdom
United States
Locations

Novartis Investigative Site
Huntsville, Alabama, United States

Novartis Investigative Site
Anchorage, Alaska, United States

Novartis Investigative Site
Glendale, Arizona, United States

Novartis Investigative Site
Fayetteville, Arkansas, United States

Novartis Investigative Site
Little Rock, Arkansas, United States

Novartis Investigative Site
Bellflower, California, United States

Novartis Investigative Site
Burbank, California, United States

Novartis Investigative Site
Gilroy, California, United States

Novartis Investigative Site
Long Beach, California, United States

Novartis Investigative Site
Long Beach, California, United States

Novartis Investigative Site
Newport Beach, California, United States

Novartis Investigative Site
San Diego, California, United States

Novartis Investigative Site
San Francisco, California, United States

Novartis Investigative Site
Santa Rosa, California, United States

Novartis Investigative Site
Stockton, California, United States

Novartis Investigative Site
Aurora, Colorado, United States

Novartis Investigative Site
Boulder, Colorado, United States

Novartis Investigative Site
Lafayette, Colorado, United States

Novartis Investigative Site
Hartford, Connecticut, United States

Novartis Investigative Site
Manchester, Connecticut, United States

Novartis Investigative Site
New Havey, Connecticut, United States

Novartis Investigative Site
Norwich, Connecticut, United States

Novartis Investigative Site
Washington, District of Columbia, United States

Novartis Investigative Site
Fort Lauderdale, Florida, United States

Novartis Investigative Site
Fort Myers, Florida, United States

Novartis Investigative Site
Fort Walton Beach, Florida, United States

Novartis Investigative Site
Gainesville, Florida, United States

Novartis Investigative Site
Hollywood, Florida, United States

Novartis Investigative Site
Jacksonville, Florida, United States

Novartis Investigative Site
Miami, Florida, United States

Novartis Investigative Site
Orlando, Florida, United States

Novartis Investigative Site
Orlando, Florida, United States

Novartis Investigative Site
Tampa, Florida, United States

Novartis Investigative Site
Augusta, Georgia, United States

Novartis Investigative Site
Brunswick, Georgia, United States

Novartis Investigative Site
Macon, Georgia, United States

Novartis Investigative Site
Marietta, Georgia, United States

Novartis Investigative Site
Tucker, Georgia, United States

Novartis Investigative Site
Honolulu, Hawaii, United States

Novartis Investigative Site
Boise, Idaho, United States

Novartis Investigative Site
Chicago, Illinois, United States

Novartis Investigative Site
Decatur, Illinois, United States

Novartis Investigative Site
Galesburg, Illinois, United States

Novartis Investigative Site
Highland Park, Illinois, United States

Novartis Investigative Site
Joliet, Illinois, United States

Novartis Investigative Site
Peoria, Illinois, United States

Novartis Investigative Site
Zion, Illinois, United States

Novartis Investigative Site
Indianapolis, Indiana, United States

Novartis Investigative Site
Bettendorf, Iowa, United States

Novartis Investigative Site
Cedar Rapids, Iowa, United States

Novartis Investigative Site
Council Bluffs, Iowa, United States

Novartis Investigative Site
Sioux City, Iowa, United States

Novartis Investigative Site
Waterloo, Iowa, United States

Novartis Investigative Site
Baton Rouge, Louisiana, United States

Novartis Investigative Site
Metairie, Louisiana, United States

Novartis Investigative Site
Portland, Maine, United States

Novartis Investigative Site
Scarborough, Maine, United States

Novartis Investigative Site
Waterville, Maine, United States

Novartis Investigative Site
Baltimore, Maryland, United States

Novartis Investigative Site
Baltimore, Maryland, United States

Novartis Investigative Site
Chevy Chase, Maryland, United States

Novartis Investigative Site
Frederick, Maryland, United States

Novartis Investigative Site
Boston, Massachusetts, United States

Novartis Investigative Site
Boston, Massachusetts, United States

Novartis Investigative Site
Fall River, Massachusetts, United States

Novartis Investigative Site
Peabody, Massachusetts, United States

Novartis Investigative Site
Ann Arbor, Michigan, United States

Novartis Investigative Site
Detroit, Michigan, United States

Novartis Investigative Site
Royal Oak, Michigan, United States

Novartis Investigative Site
Troy, Michigan, United States

Novartis Investigative Site
Duluth, Minnesota, United States

Novartis Investigative Site
Jackson, Mississippi, United States

Novartis Investigative Site
Columbia, Missouri, United States

Novartis Investigative Site
Kalamazoo, Missouri, United States

Novartis Investigative Site
Kansas City, Missouri, United States

Novartis Investigative Site
Springfield, Missouri, United States

Novartis Investigative Site
St. Louis, Missouri, United States

Novartis Investigative Site
St. Louis, Missouri, United States

Novartis Investigative Site
Billings, Montana, United States

Novartis Investigative Site
Great Falls, Montana, United States

Novartis Investigative Site
Grand Island, Nebraska, United States

Novartis Investigative Site
Lincoln, Nebraska, United States

Novartis Investigative Site
North Platte, Nebraska, United States

Novartis Investigative Site
Omaha, Nebraska, United States

Novartis Investigative Site
Omaha, Nebraska, United States

Novartis Investigative Site
Las Vegas, Nevada, United States

Novartis Investigative Site
Exeter, New Hampshire, United States

Novartis Investigative Site
Flemington, New Jersey, United States

Novartis Investigative Site
Freehold, New Jersey, United States

Novartis Investigative Site
Little Silver, New Jersey, United States

Novartis Investigative Site
Livingston, New Jersey, United States

Novartis Investigative Site
Mountain Lakes, New Jersey, United States

Novartis Investigative Site
Newark, New Jersey, United States

Novartis Investigative Site
Buffalo, New York, United States

Novartis Investigative Site
Buffalo, New York, United States

Novartis Investigative Site
East Setauket, New York, United States

Novartis Investigative Site
East Syracuse, New York, United States

Novartis Investigative Site
Fresh Meadows, New York, United States

Novartis Investigative Site
Glens Falls, New York, United States

Novartis Investigative Site
New York, New York, United States

Novartis Investigative Site
New York, New York, United States

Novartis Investigative Site
New York, New York, United States

Novartis Investigative Site
New York, New York, United States

Novartis Investigative Site
Asheville, North Carolina, United States

Novartis Investigative Site
Charlotte, North Carolina, United States

Novartis Investigative Site
Charlotte, North Carolina, United States

Novartis Investigative Site
Fayetteville, North Carolina, United States

Novartis Investigative Site
Greensboro, North Carolina, United States

Novartis Investigative Site
Bismarck, North Dakota, United States

Novartis Investigative Site
Fargo, North Dakota, United States

Novartis Investigative Site
Cincinnati, Ohio, United States

Novartis Investigative Site
Cincinnati, Ohio, United States

Novartis Investigative Site
Cleveland, Ohio, United States

Novartis Investigative Site
Columbus, Ohio, United States

Novartis Investigative Site
Columbus, Ohio, United States

Novartis Investigative Site
Sandusky, Ohio, United States

Novartis Investigative Site
Oklahoma City, Oklahoma, United States

Novartis Investigative Site
Tulsa, Oklahoma, United States

Novartis Investigative Site
Tulsa, Oklahoma, United States

Novartis Investigative Site
Klamath Falls, Oregon, United States

Novartis Investigative Site
Portland, Oregon, United States

Novartis Investigative Site
Drexel Hill, Pennsylvania, United States

Novartis Investigative Site
Philadelphia, Pennsylvania, United States

Novartis Investigative Site
Philadelphia, Pennsylvania, United States

Novartis Investigative Site
Philadelphia, Pennsylvania, United States

Novartis Investigative Site
Pittsburgh, Pennsylvania, United States

Novartis Investigative Site
Pittsburgh, Pennsylvania, United States

Novartis Investigative Site
Pottstown, Pennsylvania, United States

Novartis Investigative Site
Sayre, Pennsylvania, United States

Novartis Investigative Site
State College, Pennsylvania, United States

Novartis Investigative Site
Charleston, South Carolina, United States

Novartis Investigative Site
Columbia, South Carolina, United States

Novartis Investigative Site
Florence, South Carolina, United States

Novartis Investigative Site
Mt. Pleasant, South Carolina, United States

Novartis Investigative Site
Knoxville, Tennessee, United States

Novartis Investigative Site
Memphis, Tennessee, United States

Novartis Investigative Site
Nashville, Tennessee, United States

Novartis Investigative Site
Arlington, Texas, United States

Novartis Investigative Site
Austin, Texas, United States

Novartis Investigative Site
Austin, Texas, United States

Novartis Investigative Site
Dallas, Texas, United States

Novartis Investigative Site
Dallas, Texas, United States

Novartis Investigative Site
El Paso, Texas, United States

Novartis Investigative Site
Houston, Texas, United States

Novartis Investigative Site
Houston, Texas, United States

Novartis Investigative Site
San Antonio, Texas, United States

Novartis Investigative Site
Salt Lake City, Utah, United States

Novartis Investigative Site
Fairfax, Virginia, United States

Novartis Investigative Site
Richmond, Virginia, United States

Novartis Investigative Site
Richmond, Virginia, United States

Novartis Investigative Site
Kennewick, Washington, United States

Novartis Investigative Site
Mount Vernon, Washington, United States

Novartis Investigative Site
Seattle, Washington, United States

Novartis Investigative Site
Tacoma, Washington, United States

Novartis Investigative Site
Walla Walla, Washington, United States

Novartis Investigative Site
Morgantown, West Virginia, United States

Novartis Investigative Site
Green Bay, Wisconsin, United States

Novartis Investigative Site
La Crosse, Wisconsin, United States

Novartis Investigative Site
Marshfield, Wisconsin, United States

Novartis Investigative Site
Kogarah, New South Wales, Australia

Novartis Investigative Site
North Sydney, New South Wales, Australia

Novartis Investigative Site
Port Macquarie, New South Wales, Australia

Novartis Investigative Site
Waratah, New South Wales, Australia

Novartis Investigative Site
Westmead, New South Wales, Australia

Novartis Investigative Site
Herston, Queensland, Australia

Novartis Investigative Site
South Brisbane, Queensland, Australia

Novartis Investigative Site
Bedford Park, South Australia, Australia

Novartis Investigative Site
Hobart, Tasmania, Australia

Novartis Investigative Site
Box Hill, Victoria, Australia

Novartis Investigative Site
Fitzroy, Victoria, Australia

Novartis Investigative Site
Geelong, Victoria, Australia

Novartis Investigative Site
Wodonga, Victoria, Australia

Novartis Investigative Site
Nedlands, Western Australia, Australia

Novartis Investigative Site
Perth, Western Australia, Australia

Novartis Investigative Site
Graz, Austria

Novartis Investigative Site
Innsbruck, Austria

Novartis Investigative Site
Linz, Austria

Novartis Investigative Site
Linz, Austria

Novartis Investigative Site
Salzburg, Austria

Novartis Investigative Site
Vienna, Austria

Novartis Investigative Site
Brussel, Belgium

Novartis Investigative Site
Bruxelles, Belgium

Novartis Investigative Site
Bruxelles, Belgium

Novartis Investigative Site
Charleroi, Belgium

Novartis Investigative Site
Edegem, Belgium

Novartis Investigative Site
Gent, Belgium

Novartis Investigative Site
Haine Saint Paul, Belgium

Novartis Investigative Site
Leuven, Belgium

Novartis Investigative Site
Liège, Belgium

Novartis Investigative Site
Wilrijk, Belgium

Novartis Investigative Site
Yvoir, Belgium

Novartis Investigative Site
Salvador, Bahía, Brazil

Novartis Investigative Site
Porto Alegre, Rio Grande Do Sul, Brazil

Novartis Investigative Site
Porto Alegre, Rio Grande Do Sul, Brazil

Novartis Investigative Site
Porto Alegre, Rio Grande Do Sul, Brazil

Novartis Investigative Site
Jau, São Paulo, Brazil

Novartis Investigative Site
Rio de Janeiro, Brazil

Novartis Investigative Site
Rio de Janeiro, Brazil

Novartis Investigative Site
São Paulo, Brazil

Novartis Investigative Site
Sofia, Bulgaria

Novartis Investigative Site
Vancouver, British Columbia, Canada

Novartis Investigative Site
Winnipeg, Manitoba, Canada

Novartis Investigative Site
Moncton, New Brunswick, Canada

Novartis Investigative Site
Oshawa, Ontario, Canada

Novartis Investigative Site
Sudbury, Ontario, Canada

Novartis Investigative Site
Greenfield Park, Quebec, Canada

Novartis Investigative Site
Saskatoon, Saskatchewan, Canada

Novartis Investigative Site
Santiago, Región Metro De Santiago, Chile

Novartis Investigative Site
Guangzhou, Guangdong, China

Novartis Investigative Site
Wuhan, Hubei, China

Novartis Investigative Site
Nanjing, Jiangsu, China

Novartis Investigative Site
Dalian, Liaoning, China

Novartis Investigative Site
Hangzhou, Zhejiang, China

Novartis Investigative Site
Beijing, China

Novartis Investigative Site
Beijing, China

Novartis Investigative Site
Shanghai, China

Novartis Investigative Site
Shanghai, China

Novartis Investigative Site
Tianjin, China

Novartis Investigative Site
Strovolos, Cyprus

Novartis Investigative Site
Brno, Czech Republic

Novartis Investigative Site
Olomouc, Czech Republic

Novartis Investigative Site
Praha, Czech Republic

Novartis Investigative Site
Praha, Czech Republic

Novartis Investigative Site
Copenhagen, Denmark

Novartis Investigative Site
Odense C, Denmark

Novartis Investigative Site
Roskilde, Denmark

Novartis Investigative Site
Vejle, Denmark

Novartis Investigative Site
Århus C, Denmark

Novartis Investigative Site
Tallinn, Estonia

Novartis Investigative Site
Tartu, Estonia

Novartis Investigative Site
Helsinki, Finland

Novartis Investigative Site
Hämeenlinna, Finland

Novartis Investigative Site
Kangasala, Finland

Novartis Investigative Site
Kuopio, Finland

Novartis Investigative Site
OYS, Finland

Novartis Investigative Site
Mannheim, Baden-Wuerttemberg, Germany

Novartis Investigative Site
Stuttgart, Baden-Wuerttemberg, Germany

Novartis Investigative Site
Tuebingen, Baden-Wuerttemberg, Germany

Novartis Investigative Site
Augsburg, Bayern, Germany

Novartis Investigative Site
Marburg, Hessen, Germany

Novartis Investigative Site
Wiesbaden, Hessen, Germany

Novartis Investigative Site
Braunschweig, Niedersachsen, Germany

Novartis Investigative Site
Hannover, Niedersachsen, Germany

Novartis Investigative Site
Bonn, Nordrhein-Westfalen, Germany

Novartis Investigative Site
Duesseldorf, Nordrhein-Westfalen, Germany

Novartis Investigative Site
Ibbenbueren, Nordrhein-Westfalen, Germany

Novartis Investigative Site
Koeln, Nordrhein-Westfalen, Germany

Novartis Investigative Site
Moenchengladbach, Nordrhein-Westfalen, Germany

Novartis Investigative Site
Troisdorf, Nordrhein-Westfalen, Germany

Novartis Investigative Site
Mainz, Rheinland-Pfalz, Germany

Novartis Investigative Site
Saarbruecken, Saarland, Germany

Novartis Investigative Site
Halle, Sachsen-Anhalt, Germany

Novartis Investigative Site
Magdeburg, Sachsen-Anhalt, Germany

Novartis Investigative Site
Luebeck, Schleswig-Holstein, Germany

Novartis Investigative Site
Berlin, Germany

Novartis Investigative Site
Hamburg, Germany

Novartis Investigative Site
Athens, Greece

Novartis Investigative Site
Heraklion, Crete, Greece

Novartis Investigative Site
Maroussi, Greece

Novartis Investigative Site
Pokfulam, Hong Kong

Novartis Investigative Site
Shatin, Hong Kong

Novartis Investigative Site
Reykjavik, Iceland

Novartis Investigative Site
Jakarta, Indonesia

Novartis Investigative Site
Dublin, Ireland

Novartis Investigative Site
Dublin, Ireland

Novartis Investigative Site
Dublin, Ireland

Novartis Investigative Site
Galway, Ireland

Novartis Investigative Site
Tallaght, Dublin, Ireland

Novartis Investigative Site
Wilton, Cork, Ireland

Novartis Investigative Site
Beer-Sheva, Israel

Novartis Investigative Site
Haifa, Israel

Novartis Investigative Site
Jerusalem, Israel

Novartis Investigative Site
Petach Tikva, Israel

Novartis Investigative Site
Ramat Gan, Israel

Novartis Investigative Site
Rehovot, Israel

Novartis Investigative Site
Tel Aviv, Israel

Novartis Investigative Site
Potenza, Basilicata, Italy

Novartis Investigative Site
Reggio Calabria, Calabria, Italy

Novartis Investigative Site
Napoli, Campania, Italy

Novartis Investigative Site
Forlì, Emilia-Romagna, Italy

Novartis Investigative Site
Modena, Emilia-Romagna, Italy

Novartis Investigative Site
Aviano (PN), Friuli-Venezia-Giulia, Italy

Novartis Investigative Site
Roma, Lazio, Italy

Novartis Investigative Site
Genova, Liguria, Italy

Novartis Investigative Site
Bergamo, Lombardia, Italy

Novartis Investigative Site
Milano, Lombardia, Italy

Novartis Investigative Site
Milano, Lombardia, Italy

Novartis Investigative Site
Candiolo (TO), Piemonte, Italy

Novartis Investigative Site
Torino, Piemonte, Italy

Novartis Investigative Site
Bari, Puglia, Italy

Novartis Investigative Site
San Giovanni Rotondo (FG), Puglia, Italy

Novartis Investigative Site
Palermo, Sicilia, Italy

Novartis Investigative Site
Firenze, Toscana, Italy

Novartis Investigative Site
Pisa, Toscana, Italy

Novartis Investigative Site
Bolzano, Trentino-Alto Adige, Italy

Novartis Investigative Site
Perugia, Umbria, Italy

Novartis Investigative Site
Ancona, Italy

Novartis Investigative Site
Cagliari, Italy

Novartis Investigative Site
Chieti, Italy

Novartis Investigative Site
Macerata, Italy

Novartis Investigative Site
Padova, Italy

Novartis Investigative Site
Trieste, Italy

Novartis Investigative Site
Kyunggi-do, Korea, Republic of

Novartis Investigative Site
Pusan, Korea, Republic of

Novartis Investigative Site
seodaemun-gu, Seoul, Korea, Republic of

Novartis Investigative Site
Seoul, Korea, Republic of

Novartis Investigative Site
Seoul, Korea, Republic of

Novartis Investigative Site
songpa-gu, Seoul, Korea, Republic of

Novartis Investigative Site
Luxembourg, Luxembourg

Novartis Investigative Site
Kuala Lumpur, Malaysia

Novartis Investigative Site
Kuala Lumpur, Malaysia

Novartis Investigative Site
Petaling Jaya Selangor, Malaysia

Novartis Investigative Site
Floriana, Malta

Novartis Investigative Site
Tijuana, Baja California Norte, Mexico

Novartis Investigative Site
Toluca, Edo Mex, Estado de México, Mexico

Novartis Investigative Site
Merida, Yucatán, Mexico

Novartis Investigative Site
Durango, Mexico

Novartis Investigative Site
Mexico City, Mexico

Novartis Investigative Site
Amersfoort, Netherlands

Novartis Investigative Site
Amsterdam, Netherlands

Novartis Investigative Site
Amsterdam, Netherlands

Novartis Investigative Site
Dordrecht, Netherlands

Novartis Investigative Site
Enschede, Netherlands

Novartis Investigative Site
Groningen, Netherlands

Novartis Investigative Site
Leeuwarden, Netherlands

Novartis Investigative Site
Leiden, Netherlands

Novartis Investigative Site
Maastricht, Netherlands

Novartis Investigative Site
Christchurch, New Zealand

Novartis Investigative Site
Dunedin, New Zealand

Novartis Investigative Site
Newtown, Wellington, New Zealand

Novartis Investigative Site
Lima, Peru

Novartis Investigative Site
Lima, Peru

Novartis Investigative Site
Makati City, Philippines

Novartis Investigative Site
Pasay City, Philippines

Novartis Investigative Site
Quezon City, Philippines

Novartis Investigative Site
Sampaloc Manila, Philippines

Novartis Investigative Site
Bialystok, Poland

Novartis Investigative Site
Bydgoszcz, Poland

Novartis Investigative Site
Elblag, Poland

Novartis Investigative Site
Gdansk, Poland

Novartis Investigative Site
Gliwice, Poland

Novartis Investigative Site
Olsztyn, Poland

Novartis Investigative Site
Olsztyn, Poland

Novartis Investigative Site
Poznan, Poland

Novartis Investigative Site
Warszawa, Poland

Novartis Investigative Site
Evora, Portugal

Novartis Investigative Site
Lisboa, Portugal

Novartis Investigative Site
Lisboa, Portugal

Novartis Investigative Site
Porto, Portugal

Novartis Investigative Site
Porto, Portugal

Novartis Investigative Site
Bucharest, Romania

Novartis Investigative Site
Iasi, Romania

Novartis Investigative Site
Sibiu, Romania

Novartis Investigative Site
Timisoara, Romania

Novartis Investigative Site
Irkutsk, Russian Federation

Novartis Investigative Site
Moscow, Russian Federation

Novartis Investigative Site
Nizhny Novgorod, Russian Federation

Novartis Investigative Site
Singapore, Singapore

Novartis Investigative Site
Singapore, Singapore

Novartis Investigative Site
Singapore, Singapore

Novartis Investigative Site
Singapore, Singapore

Novartis Investigative Site
Singapore, Singapore

Novartis Investigative Site
Banska Bystrica, Slovakia

Novartis Investigative Site
Bratislava, Slovakia

Novartis Investigative Site
Bratislava, Slovakia

Novartis Investigative Site
Kosice, Slovakia

Novartis Investigative Site
Poprad, Slovakia

Novartis Investigative Site
Ljubljana, Slovenia

Novartis Investigative Site
Maribor, Slovenia

Novartis Investigative Site
Barcelona, Spain

Novartis Investigative Site
Barcelona, Spain

Novartis Investigative Site
Barcelona, Spain

Novartis Investigative Site
Basurto/Bilbao, Spain

Novartis Investigative Site
Burgos, Spain

Novartis Investigative Site
Caceres, Spain

Novartis Investigative Site
Elche, Spain

Novartis Investigative Site
Girona, Spain

Novartis Investigative Site
Jaén, Spain

Novartis Investigative Site
Lerida, Spain

Novartis Investigative Site
Madrid, Spain

Novartis Investigative Site
Madrid, Spain

Novartis Investigative Site
Madrid, Spain

Novartis Investigative Site
Malaga, Spain

Novartis Investigative Site
Murcia, Spain

Novartis Investigative Site
Palencia, Spain

Novartis Investigative Site
Palma de Mallorca, Spain

Novartis Investigative Site
Pamplona, Spain

Novartis Investigative Site
Pontevedra, Spain

Novartis Investigative Site
San Sebastián, Spain

Novartis Investigative Site
Santa Cruz de Tenerife, Spain

Novartis Investigative Site
Santiago, Spain

Novartis Investigative Site
Toledo, Spain

Novartis Investigative Site
Valencia, Spain

Novartis Investigative Site
Valencia, Spain

Novartis Investigative Site
Zaragoza, Spain

Novartis Investigative Site
Jonkoping, Sweden

Novartis Investigative Site
Lund, Sweden

Novartis Investigative Site
Stockholm, Sweden

Novartis Investigative Site
Umeå, Sweden

Novartis Investigative Site
Uppsala, Sweden

Novartis Investigative Site
Basel, Switzerland

Novartis Investigative Site
Bern, Switzerland

Novartis Investigative Site
Chur, Switzerland

Novartis Investigative Site
Geneve, Switzerland

Novartis Investigative Site
Mendrisio, Switzerland

Novartis Investigative Site
Neuchatel, Switzerland

Novartis Investigative Site
St Gallen, Switzerland

Novartis Investigative Site
Zuerich, Switzerland

Novartis Investigative Site
Kaohsiung, Taiwan

Novartis Investigative Site
Taichung, Taiwan

Novartis Investigative Site
Tainan County, Taiwan

Novartis Investigative Site
Tainan, Taiwan

Novartis Investigative Site
Taipei, Taiwan

Novartis Investigative Site
Taipei, Taiwan

Novartis Investigative Site
Taipei, Taiwan

Novartis Investigative Site
Taipei, Taiwan

Novartis Investigative Site
Taipei, Taiwan

Novartis Investigative Site
Taipei, Taiwan

Novartis Investigative Site
Bangkok, Thailand

Novartis Investigative Site
Bangkok, Thailand

Novartis Investigative Site
Chiang Mai, Thailand

Novartis Investigative Site
Pathumthani, Thailand

Novartis Investigative Site
Chernivtsi, Ukraine

Novartis Investigative Site
Kiev, Ukraine

Novartis Investigative Site
Odessa, Ukraine

Novartis Investigative Site
Rovno, Ukraine

Novartis Investigative Site
Cambridge, Cambridgeshire, United Kingdom

Novartis Investigative Site
Chelmsford, Essex, United Kingdom

Novartis Investigative Site
Northwood, Middlesex, United Kingdom

Novartis Investigative Site
Edinburgh, Midlothian, United Kingdom

Novartis Investigative Site
Belfast, United Kingdom

Novartis Investigative Site
Bournemouth, United Kingdom

Novartis Investigative Site
Brighton, United Kingdom

Novartis Investigative Site
Bristol, United Kingdom

Novartis Investigative Site
Cardiff, United Kingdom

Novartis Investigative Site
Cheltenham, United Kingdom

Novartis Investigative Site
Colchester, United Kingdom

Novartis Investigative Site
Cumbria, United Kingdom

Novartis Investigative Site
Denbighshire, United Kingdom

Novartis Investigative Site
Hartshill, Stoke-on-Trent, United Kingdom

Novartis Investigative Site
Lindley, huddersfield, United Kingdom

Novartis Investigative Site
London, United Kingdom

Novartis Investigative Site
London, United Kingdom

Novartis Investigative Site
London, United Kingdom

Novartis Investigative Site
London, United Kingdom

Novartis Investigative Site
London, United Kingdom

Novartis Investigative Site
London, United Kingdom

Novartis Investigative Site
Manchester, United Kingdom

Novartis Investigative Site
Nottingham, United Kingdom

Novartis Investigative Site
Peterborough, United Kingdom

Novartis Investigative Site
Poole, Dorset, United Kingdom

Novartis Investigative Site
Portsmouth, United Kingdom

Novartis Investigative Site
Shrewsbury, United Kingdom

Novartis Pharmaceuticals, Study Director
Novartis Pharmaceuticals

NCT Number
Keywords
advanced
TYKERB
HER2 positive
Stage IIIc
ErbB2 positive
GW572016
metastatic
Stage IIIb
breast cancer
MeSH Terms
Breast Neoplasms
Capecitabine
Lapatinib